Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab (RAPSODI)

AbbVie

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT03099083

P16-346

Details and patient eligibility

About

The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.

Enrollment: 97 patients

Sex: All

Ages: 19 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant has a diagnosis of Psoriasis by investigator.
• Participant (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.
• Participant must be able and willing to provide written informed consent and comply with the requirements of this study protocol.

Exclusion criteria

• Participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.
• Participation in any Psoriasis-related clinical trial at the time of enrolment, at baseline or at any point during the study period.
• Participants, who in the investigator's view, may not be able to accurately report their questionnaires

Trial design

97 participants in 1 patient group

Participants receiving adalimumab

Description:

Participants with Psoriasis receiving adalimumab